Your browser doesn't support javascript.
loading
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian, Yelena Y; Shitara, Kohei; Moehler, Markus; Garrido, Marcelo; Salman, Pamela; Shen, Lin; Wyrwicz, Lucjan; Yamaguchi, Kensei; Skoczylas, Tomasz; Campos Bragagnoli, Arinilda; Liu, Tianshu; Schenker, Michael; Yanez, Patricio; Tehfe, Mustapha; Kowalyszyn, Ruben; Karamouzis, Michalis V; Bruges, Ricardo; Zander, Thomas; Pazo-Cid, Roberto; Hitre, Erika; Feeney, Kynan; Cleary, James M; Poulart, Valerie; Cullen, Dana; Lei, Ming; Xiao, Hong; Kondo, Kaoru; Li, Mingshun; Ajani, Jaffer A.
Afiliación
  • Janjigian YY; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Shitara K; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Electronic address: kshitara@east.ncc.go.jp.
  • Moehler M; Department of Medicine, Johannes-Gutenberg University Clinic, Mainz, Germany.
  • Garrido M; Department of Hemato-Oncology, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile.
  • Salman P; Department of Medical Oncology, Oncovida Cancer Center, Fundación Arturo López Pérez, Providencia, Chile.
  • Shen L; Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing, Peking University Cancer Hospital and Institute, Beijing, China.
  • Wyrwicz L; Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, Poland.
  • Yamaguchi K; Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Skoczylas T; II Klinika Chirurgii Ogólnej, Gastroenterologicznej i Nowotworów Ukladu Pokarmowego, Medical University of Lublin, Lublin, Poland.
  • Campos Bragagnoli A; Department of Medical Oncology, Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Brazil.
  • Liu T; Department of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
  • Schenker M; Department of Medical Oncology, Sfantul Nectarie Oncology Center, Dolj, Romania.
  • Yanez P; Department of Internal Medicine, Oncology Unit, Universidad de La Frontera, Temuco, Chile.
  • Tehfe M; Hematology-Oncology, Oncology Center-Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada.
  • Kowalyszyn R; Instituto Multidisciplinario de Oncologia, Clinica Viedma SA, Viedma, Argentina.
  • Karamouzis MV; Department of Biological Chemistry and Laiko General Hospital Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Bruges R; Internal Medicine, Clinical Oncology, Instituto Nacional de Cancerología Empresa Social del Estado, Bogotá, Colombia.
  • Zander T; Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düesseldorf, University Hospital of Cologne, Cologne, Germany.
  • Pazo-Cid R; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Hitre E; Department of Chemotherapy, National Institute of Oncology, Budapest, Hungary.
  • Feeney K; Department of Oncology, Haematology and Palliative Care, St John of God Murdoch Hospital, Murdoch, WA, Australia.
  • Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Poulart V; Bristol Myers Squibb, Princeton, NJ, USA.
  • Cullen D; Bristol Myers Squibb, Princeton, NJ, USA.
  • Lei M; Bristol Myers Squibb, Princeton, NJ, USA.
  • Xiao H; Bristol Myers Squibb, Princeton, NJ, USA.
  • Kondo K; Bristol Myers Squibb, Princeton, NJ, USA.
  • Li M; Bristol Myers Squibb, Princeton, NJ, USA.
  • Ajani JA; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet ; 398(10294): 27-40, 2021 07 03.
Article en En | MEDLINE | ID: mdl-34102137
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Nivolumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Nivolumab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos